The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:2088 November 10, 2005 Number 19
NextNext

Retinoid X Receptor Heterodimers in the Metabolic Syndrome

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Shulman, A. I.
-PubMed Citation
To the Editor: The excellent review of nuclear receptors by Shulman and Mangelsdorf (Aug. 11 issue)1 mentioned that the study of patients with mutations in PPAR{gamma}, the gene encoding peroxisome-proliferator–activated receptor {gamma} (PPAR{gamma}), which is rare, can yield corroborating and new insights into the metabolic syndrome. However, it is important to acknowledge that all reported cases of the metabolic syndrome involving heterozygous germ-line loss-of-function PPAR{gamma} mutations2,3,4,5 concurrently have familial partial lipodystrophy type 3 (FPLD3). Given the role of PPAR{gamma} in adipogenesis, it seems reasonable that adipose tissue is repartitioned from peripheral to central stores in patients with such mutations. . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.